%0 Journal Article %A Lauren M. Lucas %A Richard L. Cullum %A Jessica A. Markham %A Joelle N. Woggerman %A Vipasha Dwivedi %A Rania H. Mohamedelhassan %A Laura J. Cook %A Connor M. Kelley %A Elizabeth L. Knerr %A David P. Kaufmann %A Megan A. Jacobi %A Darby C. Taylor %A Cristina C. Rael %A Damien S. Waits %A Taraswi M. Ghosh %A Kenneth M. Halanych %A Ram B. Gupta %A David J. Riese II %T ERBB4 Mutant Alleles May Drive BRAF WT Melanomas %D 2022 %R 10.1101/2022.06.21.22276707 %J medRxiv %P 2022.06.21.22276707 %X Metastatic skin cutaneous melanomas that contain wild-type BRAF alleles (“BRAF WT melanomas”) remain a significant clinical challenge, primarily because of the paucity of targets for therapeutic intervention. In prior work, in silico analyses of The Cancer Genome Atlas Skin Cutaneous Melanoma (TCGA-SKCM) dataset suggested that elevated transcription of the gene that encodes the ERBB4 receptor tyrosine kinase may drive BRAF WT melanomas. Moreover, that prior work demonstrated that expression of the wild-type ERBB4 gene (WT ERBB4) stimulates clonogenic proliferation by the MEL-JUSO, MeWo, and IPC-298 human BRAF WT melanoma cell lines. Moreover, expression of a dominant-negative (K751M) ERBB4 mutant (ERBB4 DN) inhibits clonogenic proliferation by the MEL-JUSO and MeWo cell lines.Here we have extended these findings by investigating the role of ERBB4 mutant alleles in BRAF WT melanomas. In silico analyses of the TCGA-SKCM BRAF WT melanoma dataset indicates that ERBB4 missense mutant alleles occur in a non-random manner, suggesting that melanomagenesis selects for the ERBB4 missense mutant alleles. Specifically, ERBB4 missense mutant alleles affect amino acid residues that are weakly correlated with residues conserved in the ERBB3 extracellular domains and the EGFR tyrosine kinase domain. The occurrence of ERBB4 missense mutant alleles in the TCGA-SKCM BRAF WT melanoma dataset is weakly inversely correlated with events that cause ERBB4-independent PI3K pathway signaling and is strongly correlated with events that cause elevated RAS pathway signaling. Thus, the in silico analyses suggest that ERBB4 mutant alleles stimulate PI3K signaling, which cooperates with elevated RAS signaling to drive BRAF WT melanomas. Moreover, the in silico analyses have prioritized the ERBB4 mutant alleles as candidate drivers of BRAF WT melanomas. One of the prioritized ERBB4 mutant alleles (P759L) stimulates greater clonogenic proliferation of MEL-JUSO cells than does WT ERBB4. Thus, our in silico prioritization strategy may effectively identify ERBB4 mutants that drive BRAF WT melanomas. Finally, the results of our in silico analyses suggest that ERBB4-dependent, BRAF WT melanomas may be effectively treated by a combination of a PI3K pathway inhibitor and a RAS pathway inhibitor.Competing Interest StatementDavid Riese has been a consultant for Eli Lilly & Company, Bristol-Myers Squibb, and ImClone SystemsFunding StatementThis research has been funded by an Auburn University Intramural Grant Program award to DJR, an Auburn University Research Initiative in Cancer (AURIC) fellowship to RLC, by the US Department of Education GAANN Graduate Fellowship Program in Biological & Pharmaceutical Engineering Award No. P200A120244 to Auburn University, an Auburn University Presidential Graduate Research Fellowship to LML, and other support from AURIC, the Department of Drug Discovery and Development, and the Harrison School of Pharmacy. DJR has been a consultant to Eli Lilly & Company, ImClone Systems, and Bristol-Myers Squibb. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:https://portal.gdc.cancer.gov/projects/TCGA-SKCMI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://portal.gdc.cancer.gov/projects/TCGA-SKCM %U https://www.medrxiv.org/content/medrxiv/early/2022/06/23/2022.06.21.22276707.full.pdf